-
1
-
-
33847053615
-
Cystic fibrosis transmembrane regulator protein mutations: 'Class' opportunity for novel drug innovation
-
MacDonald KD, McKenzie KR, Zeitlin PL Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation. Paediatr Drugs 2007; 9: 1-10.
-
(2007)
Paediatr Drugs
, vol.9
, pp. 1-10
-
-
MacDonald, K.D.1
McKenzie, K.R.2
Zeitlin, P.L.3
-
2
-
-
80455162465
-
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation
-
Ramsey BW, Davies J, McElvaney N.G., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-72.
-
(2011)
N Engl J Med
, vol.365
, pp. 1663-1672
-
-
Ramsey, B.W.1
Davies, J.2
McElvaney, N.G.3
-
3
-
-
81755163563
-
Correction of the F508del-CFTR protein processing defect in vitro by the in-vestigational drug VX-809
-
Van Goor F., Hadida S, Grootenhuis P.D., et al. Correction of the F508del-CFTR protein processing defect in vitro by the in-vestigational drug VX-809. Proc Natl Acad Sci U S A 2011; 108: 18843-8.
-
(2011)
Proc Natl Acad Sci USA
, vol.108
, pp. 18843-18848
-
-
Van Goor, F.1
Hadida, S.2
Grootenhuis, P.D.3
-
4
-
-
84926090443
-
Combined effects of VX-770 and VX-809 on several functional Abnormalities of F508del-CFTR channels
-
Kopeikin Z, Yuksek Z, Yang H.Y., Bompadre SG. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels. J Cyst Fibros 2014; 13: 508-14.
-
(2014)
J Cyst Fibros
, vol.13
, pp. 508-514
-
-
Kopeikin, Z.1
Yuksek, Z.2
Yang, H.Y.3
Bompadre, S.G.4
-
5
-
-
84937035647
-
Lumacaftorivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR
-
Wainwright CE, Elborn JS, Ramsey B.W., et al. Lumacaftorivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015; 373: 220-31.
-
(2015)
N Engl J Med
, vol.373
, pp. 220-231
-
-
Wainwright, C.E.1
Elborn, J.S.2
Ramsey, B.W.3
-
6
-
-
0028129568
-
Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
-
Fuchs HJ, Borowitz DS, Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637-42.
-
(1994)
N Engl J Med
, vol.331
, pp. 637-642
-
-
Fuchs, H.J.1
Borowitz, D.S.2
Christiansen, D.H.3
-
7
-
-
0033531143
-
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
-
Ramsey BW, Pepe MS, Quan J.M., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23-30.
-
(1999)
N Engl J Med
, vol.340
, pp. 23-30
-
-
Ramsey, B.W.1
Pepe, M.S.2
Quan, J.M.3
-
8
-
-
84919770501
-
Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein
-
Robertson SM, Luo X, Dubey N., et al. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol 2015; 55: 56-62.
-
(2015)
J Clin Pharmacol
, vol.55
, pp. 56-62
-
-
Robertson, S.M.1
Luo, X.2
Dubey, N.3
-
9
-
-
84907211027
-
Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression
-
Veit G, Avramescu RG, Perdomo D, et al Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med 2014; 6: 46ra97.
-
(2014)
Sci Transl Med
, vol.6
, pp. 46ra97
-
-
Veit, G.1
Avramescu, R.G.2
Perdomo, D.3
-
10
-
-
84907223425
-
Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis
-
Cholon DM, Quinney NL, Fulcher M.L., et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med 2014; 6: 46ra96.
-
(2014)
Sci Transl Med
, vol.6
, pp. 46ra96
-
-
Cholon, D.M.1
Quinney, N.L.2
Fulcher, M.L.3
|